Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.58 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.58 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CD69 | Q07108 | 1/20 | 0.45 |
| ▸ | MDK | P21741 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18392233 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL18784372 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL22152872 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL24080958 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL14971310 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL25098132 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL22171056 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL24046086 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL20942623 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL26877321 | 0.96 | MAPK1 (0.69) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4134433-A1 | SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT | Alnylam Pharmaceuticals, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| WO-2022140702-A1 | COMPOSITIONS OF MODIFIED TREMS AND USES THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022056127-A2 | IRNA COMPOSITIONS AND METHODS FOR SILENCING GROWTH FACTOR RECEPTOR BOUND PROTEIN 10 (GRB10) OR GROWTH FACTOR RECEPTOR BOUND PROTEIN 14 (GRB14) IN THE LIVER | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2021252649-A2 | SIRNA COMPOSITIONS AND METHODS FOR SILENCING GPAM (GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1, MITOCHONDRIAL) EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-3919619-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | Alnylam Pharmaceuticals, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| US-20210332365-A1 | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2021-10-28 | — | — | US | disclosed |
| EP-3808846-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| US-20200263183-A1 | COMPLEMENT COMPONENT iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2020-08-20 | — | — | US | disclosed |
| US-20200056175-A1 | COMPOSITIONS AND METHODS FOR INHIBITIION OF EXPRESSION OF PROTEIN C (PROC) GENES | ALNYLAM PHARMACEUTICALS, INC. | 2020-02-20 | — | — | US | disclosed |
| WO-2019014491-A1 | METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE) GENE EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-01-17 | — | — | WO | disclosed |
| WO-2018136620-A2 | ENDOSOMAL CLEAVABLE LINKERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| US-9944671-B2 | Compositions and methods directed to treating liver fibrosis | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9867882-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9796974-B2 | Modified RNAi agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332365-A1 | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | HAVCR2, EIF2AK2, ADAR | MAPK1 3616/4885LGALS3 584/4885LGALS8 253/4885 |
| US-20200263183-A1 | COMPLEMENT COMPONENT iRNA COMPOSITIONS AND METHODS OF USE THEREOF | CFB, CFH, HNRNPA2B1 | MAPK1 4806/4885LGALS3 3361/4885LGALS8 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.